This application proposes continued funding of the Harvard University Center for AIDS Research (HU CFAR). HU CFAR represents each of the Harvard affiliated schools and hospitals, including Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Children's Hospital Boston, the Immune Disease Institute, Massachusetts General Hospital, Brigham &Women's Hospital, Lemuel Shattuck Hospital, and the New England Primate Research Center. HU CFAR's goals are: 1) to consolidate and expand existing collaborations among the diverse and highly successful HU-affiliated HIV/AIDS researchers, 2) to promote new interactions and innovative research initiatives capable of more effectively addressing key AIDS research questions and 3) to attract and support the next generation of young scientists into HIV research. HU CFAR builds collaborations and provides infrastructure support to coordinate and address emerging research opportunities in basic, clinical, behavioral, and translational AIDS activities. Research emphasis among investigators includes studies of molecular virology, pathogenesis, host immune responses, epidemiology, treatment, vaccines and prevention. CFAR funding will provide administrative resources to address the most significant scientific questions in AIDS in six identified Scientific Programs: Behavioral and Social Sciences, Clinical Epidemiology and Outcomes Research, International, Pathogenesis, Therapeutics, and Vaccines. Five Core facilities have also been identified for continued HU CFAR support: Clinical, Molecular Virology/Genomics, Immunology, Biostatistics, and Small Animal Containment. In addition, the Administrative Core will provide strategic planning and fiscal oversight;the Developmental Core will support innovative pilot projects related to the goals of the scientific programs. HU CFAR will continue to expand, promote, and facilitate collaborative, multidisciplinary activities in AIDS research among CFAR members as the Harvard University model for collaborative inter-institutional interactions. Future planned activities include the development of junior investigators, expansion of the Behavioral and Social Sciences Program, development of the Molecular Virology/Genomics Core facilities, expansion of access to international clinical specimens, expansion of international research and educational activities, community outreach activities and further collaborations with other CFARs.

Public Health Relevance

The HU CFAR is a comprehensive Center providing the infrastructure to integrate Harvard University's multidisciplinary AIDS-related clinical and basic research programs. This provides a unique platform to maximize the contribution to public health by Harvard's HIV/AIDS investigators.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI060354-09
Application #
8314077
Study Section
Special Emphasis Panel (ZAI1-SV-A (J3))
Program Officer
Namkung, Ann S
Project Start
2004-07-01
Project End
2014-07-31
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
9
Fiscal Year
2012
Total Cost
$4,195,217
Indirect Cost
$499,333
Name
Harvard University
Department
Type
Organized Research Units
DUNS #
082359691
City
Cambridge
State
MA
Country
United States
Zip Code
02138
Ballandras-Colas, Allison; Brown, Monica; Cook, Nicola J et al. (2016) Cryo-EM reveals a novel octameric integrase structure for betaretroviral intasome function. Nature 530:358-61
Jain, Sachin; Oldenburg, Catherine E; Mimiaga, Matthew J et al. (2016) High Levels of Concomitant Behavioral Health Disorders Among Patients Presenting for HIV Non-occupational Post-exposure Prophylaxis at a Boston Community Health Center Between 1997 and 2013. AIDS Behav 20:1556-63
Sunshine, Sara; Kirchner, Rory; Amr, Sami S et al. (2016) HIV Integration Site Analysis of Cellular Models of HIV Latency with a Probe-Enriched Next-Generation Sequencing Assay. J Virol 90:4511-9
Krakower, Douglas S; Mayer, Kenneth H (2016) Renal Function and Tenofovir Disoproxil Fumarate for Preexposure Prophylaxis: How Safe Is Safe Enough? J Infect Dis 214:983-5
Mayer, Kenneth H; Krakower, Douglas S; Boswell, Stephen L (2016) Antiretroviral Preexposure Prophylaxis: Opportunities and Challenges for Primary Care Physicians. JAMA 315:867-8
Saito, Akatsuki; Henning, Matthew S; Serrao, Erik et al. (2016) Capsid-CPSF6 Interaction Is Dispensable for HIV-1 Replication in Primary Cells but Is Selected during Virus Passage In Vivo. J Virol 90:6918-35
Krakower, Douglas S; Maloney, Kevin M; Grasso, Chris et al. (2016) Primary care clinicians' experiences prescribing HIV pre-exposure prophylaxis at a specialized community health centre in Boston: lessons from early adopters. J Int AIDS Soc 19:21165
Brown, Carolyn A; Suneja, Gita; Tapela, Neo et al. (2016) Predictors of Timely Access of Oncology Services and Advanced-Stage Cancer in an HIV-Endemic Setting. Oncologist 21:731-8
McDavitt, Bryce; Bogart, Laura M; Mutchler, Matt G et al. (2016) Dissemination as Dialogue: Building Trust and Sharing Research Findings Through Community Engagement. Prev Chronic Dis 13:E38
Gandhi, Rajesh T; Kwon, Douglas S; Macklin, Eric A et al. (2016) Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial. J Acquir Immune Defic Syndr 71:246-53

Showing the most recent 10 out of 844 publications